Assess whether scientific advice should be sought before the next trial

SITUATION The working file is CMC comparability package for a site change after a literature paper the 505(b)(2) package leans on getting retracted. Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences CMC and Development Pathways file.

DECISION Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using CMC comparability package for a site change after a literature paper the 505(b)(2) package leans on getting retracted.

HYPOTHESES TO TEST 1. Clinical-development physician can defend Proceed under protocol from CMC comparability package for a site change after a literature paper the 505(b)(2) package leans on getting retracted in a Pharma & Life Sciences challenge. 2. Clinical-development physician cannot defend Proceed under protocol from CMC comparability package for a site change; Pause the pathway is what the extract actually supports after a literature paper the 505(b)(2) package leans on getting retracted. 3. A literature paper the 505(b)(2) package leans on getting retracted never reached the population in CMC comparability package for a site change — reopen intake, do not close scientific advice should be. 4. Two facts in CMC comparability package for a site change after a literature paper the 505(b)(2) package leans on getting retracted conflict for clinical-development physician; hold this CMC and Development Pathways file.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on scientific advice should be. 2. Check whether CMC comparability package for a site change supports the labeled claim clinical-development physician would keep. 3. Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read CMC comparability package for a site change against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move scientific advice should be for clinical-development physician.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (CMC comparability package for a site change after a literature paper the 505(b)(2) package leans on getting retracted). The follow-on CMC and Development Pathways action is what clinical-development physician does next: implement the option, assign an owner, and log the missing fact.